The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 4, 2006, Pages

  Altice, Frederick L ^a,d   Sullivan, Lynn E ^a   Smith Rohrberg, Duncan ^a   Basu, Sanjay ^a   Stancliff, Sharon ^b   Eldred, Lois ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Harm Reduction Coalition   (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; METHADONE;

EPIDEMIC; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; METHADONE TREATMENT; OPIATE ADDICTION; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SEXUAL BEHAVIOR; SUBSTANCE ABUSE;

BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 33845403539     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508181     Document Type: Review

References (80)

1. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981; 305:1431-8.
2. Stancliff S. Buprenorphine and the tratment of opioid addiction. PRN Notebook 2004; 9:28-32.
3. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2003 National Survey on Drug Use and Health: national findings. Rockville, MD: SAMHSA, 2004.
4. Fiellin DA, O'Connor PG. Clinical practice: office-based treatment of opioid-dependent patients. N Engl J Med 2002; 347:817-23.
5. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23:93-105.
6. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:329-32.
7. Centers for Disease Control and Prevention. HIV diagnoses among injection-drug users in states with HIV surveillance - 25 states, 1994-2000. MMWR Morb Mortal Wkly Rep 2003; 52:634-6.
8. Kozal MJ, Amico KR, Chiarella J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr 2005; 40:106-9.
9. Fisher JD, Cornman DH, Osborn CY, Amico KR, Fisher WA, Friedland GA. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: formative research, acceptability, and fidelity of the Options Project. J Acquir Immune Defic Syndr 2004; 37(Suppl 2):S78-87.
10. Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S154-7.
11. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2002; 4:CD002207.
12. Yoast R, Williams MA, Deitchman SD, Champion HC. Report of the Council on Scientific Affairs: methadone maintenance and needle-exchange programs to reduce the medical and public health consequences of drug abuse. J Addict Dis 2001; 20:15-40.
13. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002; 28:231-41.
14. Gossop M, Stewart D, Browne N, Marsden J. Methadone treatment for opiate dependent patients in general practice and specialist clinic settings: outcomes at 2-year follow-up. J Subst Abuse Treat 2003; 24:313-21.
15. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290.
16. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17.
17. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry 2001; 158:1200-4.
18. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991; 17:119-28.
19. Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004; 27:153-9.
20. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 2006; 42:716-21.
21. Johnson TP, Booth AL, Johnson P. Physician beliefs about substance misuse and its treatment: findings from a U.S. survey of primary care practitioners. Subst Use Misuse 2005; 40:1071-84.
22. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005; 165:618-23.
23. Park ER, Wolfe TJ, Gokhale M, Winickoff JP, Rigotti NA. Perceived preparedness to provide preventive counseling: reports of graduating primary care residents at academic health centers. J Gen Intern Med 2005; 20:386-91.
24. Kern DE, Branch WT Jr, Jackson JL, et al. Teaching the psychosocial aspects of care in the clinical setting: practical recommendations. Acad Med 2005; 80:8-20.
25. Kulik TB, Kobylecka E, Modzelewska T, Kachaniuk H, Stefanowicz A. Primary health care physicians' knowledge of prophylactics of drug abuse. Ann Univ Mariae Curie Sklodowska [Med] 2003; 58:220-6.
26. Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Making 2001; 21:28-36.
27. Miller NS, Sheppard LM, Colenda CC, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med 2001; 76:410-8.
28. Bruce RD, Altice FL. Editorial comment: why treat three conditions when it is one patient? AIDS Read 2003; 13:378-9.
29. Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E. Initiation and continuation of newer antiretroviral treatments among Medicaid recipients with AIDS. J Gen Intern Med 2001; 16:850-9.
30. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37:714-22.
31. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
32. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74.
33. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-9.
34. Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003; 33:321-8.
35. Kerr T, Marshall A, Walsh J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005; 17:539-49.
36. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS 2005; 19:326-34.
37. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction 2004; 99:361-8.
38. Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care: an implementation evaluation. J Gen Intern Med 2005; 20:344-9.
39. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med 2004; 164:277-88.
40. Herman M, Gourevitch MN. Integrating primary care and methadone maintenance treatment: implementation issues. J Addict Dis 1997; 16:91-102.
41. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med 1992; 93:382-6.
42. Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 1999; 13:2069-74.
43. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998; 12:967-71.
44. O'Connor PG, Samet JH. The substance-using human immunodeficiency virus patient: approaches to outpatient management. Am J Med 1996; 101:435-44.
45. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep 1993; 108:492-500.
46. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med 1989; 111:761-3.
47. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40(Suppl 5):S276-85.
48. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Aust N Z J Public Health 2004; 28:576-8.
49. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS 2000; 14:151-5.
50. Rollnick S, Mason P, Butler C. Health behavior change: a guide for practitioners. Edinburgh: Churchill Livingstone, 1999.
51. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001; 28:345-50.
52. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35:46-51.
53. Antela A. Access to antiretroviral therapy in HIV-infected injection drug users. AIDS 2001; 15:1727-8.
54. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1707-15.
55. Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr 1999; 22:461-6.
56. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res 2000; 35:389-416.
57. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 2005; 165:1769-76.
58. Metrebian N, Shanahan W, Wells B, Stimson GV. Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. Med J Aust 1998; 168:596-600.
59. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88:34-9.
60. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003; 179:38-42.
61. De Castro S, Sabate E. Adherence to heroin dependence therapies and human immunodeficiency virus/acquired immunodeficiency syndrome infection rates among drug abusers. Clin Infect Dis 2003; 37(Suppl 5):S464-7.
62. Camacho LM, Bartholomew NG, Joe GW, Simpson DD. Maintenance of HIV risk reduction among injection opioid users: a 12 month post-treatment follow-up. Drug Alcohol Depend 1997; 47:11-8.
63. Meandzija B, O'Connor PG, Fitzgerald H, Rounsaville BJ, Kosten TR. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 1994; 36:109.
64. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6:1049-56.
65. Watkins KE, Metzger D, Woody G, McLellan AT. Determinants of condom use among intravenous drug users. AIDS 1993; 7:719-23.
66. Lollis CM, Strothers HS, Chitwood DD, McGhee M. Sex, drugs, and HIV: does methadone maintenance reduce drug use and risky sexual behavior? J Behav Med 2000; 23:545.
67. Avants SK, Margolin A, Usubiaga MH, Doebrick C. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat 2004; 26:67-78.
68. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol 2003; 22:223-8.
69. Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict 2001; 10:69-78.
70. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; 2:CD002207.
71. Marsch LA, Bickel WK, Badger GJ, Jacobs EA. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005; 77:195-204.
72. Bryan AD, Fisher JD, Fisher WA, Murray DM. Understanding condom use among heroin addicts in methadone maintenance using the information-motivation- behavioral skills model. Subst Use Misuse 2000;35:451-71.
73. Des Jarlais DC. "Single-use" needles and syringes for the prevention of HIV infection among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S52-6.
74. Springer KW, Sterk CE, Jones TS, Friedman L. Syringe disposal options for injection drug users: a community-based perspective. Subst Use Misuse 1999; 34:1917-34.
75. Mitka M. Office-based primary care physicians called on to treat the "new" addict. JAMA 2003; 290:735.
76. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006; 43(Suppl 4):S191-6 (in this supplement).
77. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361:662-8.
78. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003; 71:295-302.
79. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001; 96:1267-78.
80. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;3:CD002207.